| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 04/19/2006 | EP1646394A2 Methods of treatment with lxr agonists |
| 04/19/2006 | EP1646388A2 Cytotoxic indeno and isoindoloisoquinolones |
| 04/19/2006 | EP1646385A2 Use of benzothiopenes to treat and prevent prostate cancer |
| 04/19/2006 | EP1646382A2 Compounds, compositions and methods |
| 04/19/2006 | EP1646381A2 Combination therapy for treating chronic inflammatory diseases |
| 04/19/2006 | EP1646380A2 Indolocarbazole anticancer agents and methods of using same |
| 04/19/2006 | EP1646377A2 Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator |
| 04/19/2006 | EP1646371A2 Antiviral compounds and methods |
| 04/19/2006 | EP1646367A2 Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention |
| 04/19/2006 | EP1646357A2 Pro104 antibody compositions and methods of use |
| 04/19/2006 | EP1646355A2 Pharmaceutical formulations |
| 04/19/2006 | EP1646354A2 Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
| 04/19/2006 | EP1646353A2 Fusion proteins for the treatment of cns |
| 04/19/2006 | EP1646352A2 Cell permeable conjugates of peptides for inhibition of protein kinases |
| 04/19/2006 | EP1646328A2 Treatment of dependence withdrawal |
| 04/19/2006 | EP1294724B1 Pyrrolo¬2,3-d|pyrimidine compounds as immunosuppressive agents |
| 04/19/2006 | EP1143940B1 Compositions and methods for mucosal delivery |
| 04/19/2006 | CN1761759A Optimized expression of HPV 31 L1 in yeast |
| 04/19/2006 | CN1761487A Dispersible formulation of an anti-inflammatory agent |
| 04/19/2006 | CN1761479A Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy |
| 04/19/2006 | CN1761477A Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
| 04/19/2006 | CN1251707C Application of Engally nut oil in the preparation of medicine for treating arthritis |
| 04/19/2006 | CN1251680C Compositions comprising cytosine derivatives for the treatment of cancer |
| 04/18/2006 | USRE39069 Capable of delivering a first active agent in an outer lamina to one environment of use and a second active agent in the core to another environment of use; An erodible polymer coat between internal semipermeable membrane and a second active agent containing vinyl acetate-vinylpyrrolidone copolymer |
| 04/18/2006 | US7030240 Piperidinylamino-thieno[2,3-d] pyrimidine compounds |
| 04/18/2006 | US7030141 Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| 04/18/2006 | US7030133 Inhibitors of formation of advanced glycation endproducts (AGEs) |
| 04/18/2006 | US7029694 Compositions and methods for transdermal oxybutynin therapy |
| 04/18/2006 | US7029678 Vaccines |
| 04/13/2006 | WO2005051319A3 Plks as modifiers of the beta catenin pathway and methods of use |
| 04/13/2006 | WO2005032460A3 Human epo mimetic hinge core mimetibodies, compositions, methods and uses |
| 04/13/2006 | WO2005030138A3 Methods of modulating inflammatory reactions by modulating xanthine oxidoreductase activity |
| 04/13/2006 | WO2005025502A3 A method for treating or inhibiting the effects of injuries or diseases that result in neuronal degeneration |
| 04/13/2006 | WO2005009392A3 Dihydropyrimidone inhibitors of calcium channel function |
| 04/13/2006 | WO2005002507A3 Modulation of survivin expression |
| 04/13/2006 | WO2005000213A3 Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors |
| 04/13/2006 | US20060079539 Synergistic combination |
| 04/13/2006 | US20060079489 Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine |
| 04/13/2006 | US20060079471 Snornai-small nucleolar rna degradation by rna interference in trypanosomatids |
| 04/13/2006 | US20060078575 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 04/13/2006 | US20060078572 M. haemolytica outer membrane protein P1pE as a vaccine or vaccine component against shipping fever |
| 04/13/2006 | US20060078087 Treatment of age-related macular degeneration |
| 04/12/2006 | EP1644729A2 Anti-cd74 immunoconjugates and methods |
| 04/12/2006 | EP1644393A2 Novel lincomycin derivatives possessing antimicrobial activity |
| 04/12/2006 | EP1644370A2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| 04/12/2006 | EP1644335A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| 04/12/2006 | EP1644323A2 Histone deacetylase inhibitors and methods of use thereof |
| 04/12/2006 | EP1644316A2 2-aminobenzoyl derivatives |
| 04/12/2006 | EP1644048A2 Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
| 04/12/2006 | EP1644039A2 Compositions and methods for treating coagulation related disorders |
| 04/12/2006 | EP1644038A2 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
| 04/12/2006 | EP1644024A2 Antimicrobial flush solutions |
| 04/12/2006 | EP1644021A2 Methods and compositions for the treatment of gastrointestinal disorders |
| 04/12/2006 | EP1644020A2 Lyase treatment for p. carinii |
| 04/12/2006 | EP1644009A2 Compositions and methods for increasing telomerase activity |
| 04/12/2006 | EP1644004A2 Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
| 04/12/2006 | EP1644001A2 Pancratistatin cyclic phosphate prodrugs an phenpanstatin cyclic phosphate prodrugs |
| 04/12/2006 | EP1643994A2 Methods for inhibiting or reversing tau filament fibrillization |
| 04/12/2006 | EP1643993A2 Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
| 04/12/2006 | EP1643986A2 Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer s disease |
| 04/12/2006 | EP1643984A2 Use of parthenolide derivatives as antileukemic and cytotoxic agents |
| 04/12/2006 | EP1643981A2 Antiviral compositions and methods of using the same |
| 04/12/2006 | EP1643969A2 Compositions and methods for hydrophobic drug delivery |
| 04/12/2006 | EP1643961A2 Cox-2 and faah inhibitors |
| 04/12/2006 | EP1643959A2 Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment |
| 04/12/2006 | EP1643958A2 Method for selective targeting of apoptotic cells and small molecule ligands used thereof |
| 04/12/2006 | EP1643953A2 Regulation of matrix metalloproteinase gene expression using specific and selective electrical and electromagnetic signals |
| 04/12/2006 | EP1643946A2 Compositions for and methods for treating hiv |
| 04/12/2006 | EP1545690A4 Selective plasma exchange therapy |
| 04/12/2006 | EP1401828B1 N-formyl hydroxylamine compounds as inhibitors of pdf |
| 04/12/2006 | CN1759190A Absolute quantitation of nucleic acids by RT-PCR |
| 04/12/2006 | CN1759116A Pyridyloxymethyl and benzisoxazole azabicyclic derivatives |
| 04/12/2006 | CN1759095A N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| 04/12/2006 | CN1758922A Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| 04/12/2006 | CN1758900A Pharmaceutical composition |
| 04/12/2006 | CN1250559C Process for preparing amine platinum complexes |
| 04/12/2006 | CN1250226C Pharmaceutical combination comprising either (S)-20ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tboc amino-phenyl)ethoxy]phenyl}-(S)-2-ethoxy propionic ac |
| 04/12/2006 | CN1250223C Pyrrolo-triazine and pyrimidine compounds |
| 04/12/2006 | CN1250215C Carbamate compounds for use in preventing or treating bipolar disorder |
| 04/11/2006 | US7026356 Fatty acid analogues for the treatment of diseases caused by the pathological proliferation of smooth muscle cells |
| 04/11/2006 | US7026303 xylose or arabinose surrounded by a hydrophobic layer and/or a hydrophilic layer, used for normalizing bowel function, inducing laxation, providing dietary fiber, and/or reducing serum cholesterol levels |
| 04/11/2006 | US7025949 In-vivo diagnostic method by means of near infrared radiation |
| 04/11/2006 | CA2199117C Compounds and methods for the treatment of cancer |
| 04/06/2006 | WO2005115304A3 Use of c-kit inhibitors for treating fibrodysplasia |
| 04/06/2006 | WO2005037193A8 Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury |
| 04/06/2006 | WO2005013917A3 Combination therapy for treating alphavirus infection and liver fibrosis |
| 04/06/2006 | WO2005004794A8 Method of treating neurodegenerative disease |
| 04/06/2006 | WO2005000225A3 Production of rabies antibodies in plants |
| 04/06/2006 | US20060074120 cyclopent[f]pyrazole derivatives; antiinflammatory agent; autoimmune diseases; side effect reduction, advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity or metabolism |
| 04/06/2006 | US20060074112 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors |
| 04/06/2006 | US20060074040 Administering an immunostimulatory oligonucleotide or an immunomer compound and treating with ionizing or gamma radiation; antiinflammatory, anticarcinogenic, antitumor, antihistamine, antiallergen, and bronchodilator agents; autoimmune, respiratory system, and skin disorders; cytokine immunotherapy |
| 04/06/2006 | US20060073207 Protein biomaterials and biocoacervates and methods of making and using thereof |
| 04/06/2006 | US20060073167 Vaccine for fish cold-water disease |
| 04/06/2006 | US20060073137 Humanised antibodies |
| 04/06/2006 | US20060073136 Humanised antibodies |
| 04/06/2006 | US20060070191 Composition for dyeing keratinous fibres with a cationic direct dye and a nonionic surfactant |
| 04/05/2006 | EP1642902A2 Method of obtaining taxosteroids and precursors thereof |
| 04/05/2006 | EP1641927A2 Induced activation in dendritic cells |
| 04/05/2006 | EP1641766A2 Novel chemical compounds |
| 04/05/2006 | EP1641748A2 N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease |